Fig. 2From: Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot studyPathological response rate in patients with locally advanced ESCC. TRG rate (a), pCR rate and R0 resection rate (b) of neoadjuvant camrelizumab plus chemotherapy in locally advanced ESCC. TRG, tumor regression rate; pCR, pathological complete response; ESCC, esophageal squamous cell carcinomaBack to article page